- Biogen's high-risk bet on Alzheimer's a potential game changer
- The EMA at 20: A short history of the European Medicines Agency
- INTERVIEW: Pre Diagnostics takes new approach to Alzheimer's blood test
- US Capitol Capsule: Time for optimism about Alzheimer's R&D?
ANALYSIS Other Informa Analysis
- PROFILE: Tuomo Pätsi describes Celgene's evolution and the emotional fallout of M&A
- Profile: Dr Reddy's CEO on mass exits, listening to parents & architecture